Cooperative Agreement U43CA186118

Federal Grant Award Summary The National Cancer Institute awarded a $410,933 Project Grant (CFDA 93.395, Cancer Treatment Research) to the University of California, San Diego on March 18, 2026, for the development of next-generation small interfering RNA (siRNA) therapeutics to treat metastatic castration-resistant prostate cancer (mCRPC). Under this exploratory research initiative (R21), the institution is developing enhanced siRNA delivery technologies designed to increase tumor cell...

Veramorph LLC received a $399,985 Project Grant Award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on September 10, 2025, with completion targeted for August 31, 2026. The award supports preclinical validation of an oral fulvestrant formulation designed to improve endocrine therapy for estrogen receptor-positive (ER+) metastatic breast cancer patients. Fulvestrant is a selective estrogen receptor degrader (SERD) currently administered as a...

This Project Grant award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Targeting Systems to develop a novel intramuscular gene delivery platform capable of sustained expression and endogenous secretion of bispecific natural killer cell engager (BIKE) therapeutics to treat solid tumors like hepatocellular carcinoma. The platform aims to deliver BIKEs in a less invasive manner than current immunotherapies,...

Federal Grant Award Summary The National Cancer Institute (NCI) awarded Natsar Pharmaceuticals, Inc. a $1.63 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) on September 22, 2025, for the development of RK-33, a small molecule inhibitor targeting DDX3 (DEAD-box helicase 3) as a therapeutic candidate for triple-negative breast cancer (TNBC). The grant supports drug development activities through August 31, 2027, advancing a rationally designed compound that has...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) award of $274,947 to Lattice Therapeutics Inc. supports the development of a customizable, next-generation RNA delivery particle. The project aims to validate the ability of an engineerable protein nanoparticle platform to efficiently and specifically deliver RNA cargoes to target cancer cells. Key objectives include in vitro evaluation of RNA...

Federal Project Grant Award Summary Brigham & Women's Hospital, in partnership with Dana-Farber Cancer Institute (DFCI), received a $772,208 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to conduct translational research on macrophage-directed therapeutic strategies for BRCA-associated breast cancer. The award, dated April 10, 2026, with ultimate completion by March 31, 2031, supports validation and advancement of a...

Gigamune, Inc. received an $800,000 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded September 15, 2025, with completion targeted for August 31, 2026. Under the direction of Principal Investigator David Scott Johnson, Ph.D., the company is developing a novel lentiviral vector technology for enhanced in vivo delivery of T cell receptors (TCRs) to address treatment limitations in Stage IV metastatic melanoma. The project builds...

Federal Grant Award Summary Pearl Scientific Inc. received a $392,695 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective September 18, 2025 through August 31, 2026. The company is developing humanized monoclonal antibodies (mAbs) that antagonize Semaphorin 7A (SEMA7A) as a therapeutic approach for breast cancer treatment. The research focuses on identifying and validating SEMA7A-antagonist mAbs with high binding affinity,...

Grant Award Summary Texas State University received a $531,550 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded July 4, 2025, with completion targeted for June 30, 2028. The grant funds research to discover novel druggable targets for neuroblastoma differentiation therapy from the human druggable genome. The primary deliverable is the identification of differentiation-blocking oncogenes through systematic screening of small...

Grant Award Summary The National Cancer Institute awarded Tiba Biotech LLC a $399,300 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on September 10, 2025, with a completion date of August 31, 2026. The award supports development and preclinical testing of an innovative cancer immunotherapy platform combining enhanced self-amplifying RNA (esRNA) encoding tumor antigens with spleen-targeted biodegradable nanoparticle delivery systems. Tiba's proprietary dendritic...